Signaling pathways and inhibitors of cells from patients with kaposiform lymphangiomatosis.
Elisa BoscoloPatricia PasturaKathryn GlaserJillian GoinesAdrienne M HammillDenise M AdamsPeter DickieBelinda Hsi DickieTimothy D Le CrasPublished in: Pediatric blood & cancer (2019)
Our studies using cells from KLA patient lesions demonstrate that these cells are highly proliferative and the PI3K-AKT-mTOR and MAPK pathways are promising therapeutic targets. Development and clinical trials of PI3K, AKT, and MAPK inhibitors for cancer treatment and the data in this study lend support for early clinical trials assessing the efficacy of these inhibitors in KLA patients.
Keyphrases
- pi k akt
- signaling pathway
- cell cycle arrest
- induced apoptosis
- clinical trial
- cell proliferation
- end stage renal disease
- epithelial mesenchymal transition
- newly diagnosed
- ejection fraction
- oxidative stress
- chronic kidney disease
- electronic health record
- randomized controlled trial
- cell death
- machine learning
- open label
- big data
- patient reported